Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease

Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson’s disease

“…10 In the present study, we used this well characterized experimental paradigm to validate an in vivo imaging procedure to track stem cells using a near-infrared platform. To the best of our knowledge, this is the first study that addresses the use of near-infrared technology to track the fate, in living parkinsonian animals, of near-infrared-labeled cells following two different administration routes, ie, intrastriatal and intranasal.…”

“…9 Grafted cells also positively and dosedependently influenced endogenous neurogenesis, sustaining the commitment of neural progenitors towards neurons. 10 Near-infrared light imaging offers new opportunities as a sensitive and noninvasive detection technique for diagnostics. This technology holds enormous potential for a wide variety of in vivo applications and is being increasingly used in small animal research.…”

Stem Cells for the Treatment of Neuropathic Pain

“…An interesting note is that stem cells, regardless of their sources, can secrete neurotrophic factors. For example, human mesenchymal stem/ stromal cells (hMSCs) produce at least 84 trophic factors including epidermal growth factor (EGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), ciliary neurotrophic factor (CNTF), basic fibroblast growth factor (bFGF/FGF-2), hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF) (24). Further, these neurotrophic factors have also been released by ASCs and other stem cells (25).…”

The Pharmacology of Regenerative Medicine

“…The effect of various cell sources have been investigated in animal models of PD, as well as in humans, and these include, embryonic stem (ES) cells (Freed et al, 2001;Kim et al, 2002, see Lindvall and, induced pluripotent stem (iPS) cells (Wernig et al, 2008), fetal and adult brain-derived neural stem cells (NSC; Hermann et al, 2006;Schwarz et al, 2006), mesenchymal stem cells (MSC; Hellmann et al, 2006;Cova et al, 2010), and amniotic fluid stem (AFS) cells (Donaldson et al, 2009). In an interesting application of regenerative pharmacology, neural progenitors generated from pluripotent stem cells in culture were induced to give rise to dopaminergic neurons, which hold therapeutic potential for PD.…”